Westview Management dba Westview Investment Advisors Makes New $2.36 Million Investment in Boston Scientific Corporation $BSX

Westview Management dba Westview Investment Advisors bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 4th quarter, Holdings Channel reports. The firm bought 24,780 shares of the medical equipment provider’s stock, valued at approximately $2,363,000.

A number of other hedge funds have also recently modified their holdings of the business. Brighton Jones LLC lifted its stake in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the last quarter. Personal CFO Solutions LLC grew its position in Boston Scientific by 28.8% in the 2nd quarter. Personal CFO Solutions LLC now owns 2,793 shares of the medical equipment provider’s stock valued at $300,000 after acquiring an additional 624 shares during the last quarter. Magnetar Financial LLC grew its position in Boston Scientific by 15.9% in the 2nd quarter. Magnetar Financial LLC now owns 5,782 shares of the medical equipment provider’s stock valued at $621,000 after acquiring an additional 794 shares during the last quarter. Hillsdale Investment Management Inc. increased its stake in Boston Scientific by 14.9% in the second quarter. Hillsdale Investment Management Inc. now owns 6,950 shares of the medical equipment provider’s stock worth $746,000 after purchasing an additional 900 shares during the period. Finally, Evelyn Partners Investment Management LLP lifted its position in shares of Boston Scientific by 289.1% during the second quarter. Evelyn Partners Investment Management LLP now owns 5,070 shares of the medical equipment provider’s stock worth $496,000 after purchasing an additional 3,767 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BSX. UBS Group lowered their target price on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Jefferies Financial Group reiterated a “buy” rating on shares of Boston Scientific in a report on Monday, March 16th. Stifel Nicolaus lowered their price objective on shares of Boston Scientific from $110.00 to $90.00 and set a “buy” rating for the company in a research report on Friday. Sanford C. Bernstein restated an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a research note on Friday, February 6th. Finally, Argus raised shares of Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $106.27.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $69.54 on Monday. The firm has a market cap of $103.34 billion, a P/E ratio of 35.84, a P/E/G ratio of 0.97 and a beta of 0.69. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 12 month low of $67.56 and a 12 month high of $109.50. The stock’s fifty day moving average price is $79.74 and its 200-day moving average price is $91.94.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the previous year, the company posted $0.70 earnings per share. The firm’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Needham/analyst support — Needham & Company maintained a Buy rating and $97 price target, arguing the financial fallout from the Accolade pacemaker recalls is limited and supports a continued Buy stance. Boston Scientific: Limited Financial Fallout From Pacemaker Recalls Supports Continued Buy Rating
• Neutral Sentiment: Stifel trims target but keeps Buy — Stifel cut its price target from $110 to $90 while retaining a Buy rating, reducing upside expectations even as the firm remains constructive. Benzinga: Stifel Nicolaus Price Target
• Neutral Sentiment: Other firms lower expectations — Truist and UBS have lowered price targets/expectations (Truist to $92), signaling more cautious analyst views on near-term growth despite mixed analyst conviction. Truist Lowers Boston Scientific Price Target to $92
• Negative Sentiment: Multiple securities class-action alerts — Several law firms have filed or are soliciting lead plaintiffs for securities fraud suits tied to disclosures covering July 2025–Feb 2026; reminders and deadlines (May 4, 2026) are fueling legal uncertainty and potential future liability. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: NYT report alleges long-standing battery issues — The New York Times reports Boston Scientific was aware of pacemaker battery problems for years, a story that raises reputational and regulatory risk beyond the company’s stated scope. Boston Scientific Knew of Pacemaker Battery Problems for Years
• Negative Sentiment: Recall expanded — Market chatter notes Boston Scientific amended its Accolade pacemaker recall, increasing the affected population to ~1.6 million devices, which raises potential remediation costs and investor concern. Market Chatter: Boston Scientific Amends Recall of Accolade Pacemakers, Affected Population Now 1.6 Million
• Negative Sentiment: High-profile criticism — Jim Cramer publicly criticized BSX’s recent performance and competitive pressures, a sentiment that can influence retail flows and short-term sentiment. Jim Cramer on Boston Scientific: “This Stock Was One of the Greatest Performers, It’s Not Anymore”

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.